Charcot neuro-osteoarthropathy (CN) is one of the most consequential and most frequently missed complications of diabetes-related peripheral neuropathy. In its active phase it presents as a warm, swollen, erythematous foot that often looks like cellulitis or gout and feels deceptively minor to a patient who has lost protective sensation. Left unrecognized for even a few weeks, the underlying bone and joint destruction can progress to fixed deformity, ulceration, osteomyelitis and amputation. Understanding how CN is identified and managed is therefore central to limb preservation in people with diabetes.
Why Early Recognition Matters
The 2023 guidelines from the International Working Group on the Diabetic Foot (IWGDF) — the first IWGDF document devoted specifically to active Charcot neuro-osteoarthropathy — emphasize that diagnosis in the acute phase rests on clinical suspicion rather than on any single test. Wukich and colleagues recommend that any person with diabetes and peripheral neuropathy presenting with a unilaterally red, hot, swollen foot or ankle be considered to have active CN until proven otherwise, with immediate offloading initiated while the diagnostic work-up proceeds (Wukich et al., Diabetes/Metabolism Research and Reviews, 2023).
The clinical stakes are not static. A retrospective analysis of Texas hospital discharge data by Cole and Jupiter found that both overall and age-standardized rates of diabetic CN rose across most years between 2006 and 2016, and that major and minor amputations among patients with CN increased over the same period (Cole & Jupiter, Primary Care Diabetes, 2024). The authors attribute part of this pattern to inconsistent diagnostic and management pathways across settings.
The Diagnostic Challenge
Because the presenting signs of active CN overlap so closely with infection, misdiagnosis runs in both directions. Bansod and colleagues describe the characteristic combination of insidious onset, painless or disproportionately painless swelling, and joint deformity that mimics other musculoskeletal conditions, and note that autonomic dysfunction with increased local blood flow contributes to the bone resorption that drives collapse (Bansod et al., Cureus, 2023).
A case series by Pham and colleagues illustrates the opposite error. Three neuropathic patients with foot ulcers developed post-surgical swelling and radiographic fragmentation that raised concern for osteomyelitis. The treating team maintained a diagnosis of Charcot neuroarthropathy and managed all three with immobilization and offloading alone; the fragmentation resolved without antibiotics or surgery (Pham et al., Wounds, 2023). Distinguishing the two conditions materially changes treatment — and in this instance avoided unnecessary bone resection.
Plain radiographs remain the first-line image, but early active CN may show no bony change at all. Advanced imaging, particularly MRI, is used when radiographs are normal despite strong clinical suspicion, and skin temperature difference between the affected and contralateral foot is a widely used bedside marker of ongoing activity.
Offloading and Conservative Management
Nonsurgical care remains the mainstay of treatment for active CN and is successful in most cases. Schweitzer and Rockhill outline the core principles: immobilization and non-weight-bearing should begin as soon as the diagnosis is entertained, and should continue until the affected bones and joints have coalesced — a process typically monitored by resolution of temperature asymmetry and swelling alongside serial radiographs (Schweitzer & Rockhill, Clinics in Podiatric Medicine and Surgery, 2022). Total contact casting is the most commonly used device. Treatment durations are measured in months, not weeks, and premature return to weight-bearing is a recognized cause of deformity progression.
The same authors emphasize that patient education and expectation management are decisive. Adherence to prolonged offloading is difficult, and the reasons for it are not intuitive to a patient whose foot does not hurt. Adjunctive pharmacologic agents such as bisphosphonates and calcitonin have been studied, but the IWGDF review found the evidence insufficient to recommend them as routine treatment.
When Reconstruction Is Considered
Surgery is reserved primarily for chronic deformity that cannot be accommodated in footwear or bracing, recurrent ulceration over bony prominences, or instability. Spingola and colleagues note that reconstruction of the Charcot foot and ankle demands rigid fixation, resection of diseased bone and accurate anatomic alignment, and that the operating surgeon needs concurrent command of vascular assessment, infection management and soft-tissue technique (Spingola et al., Clinics in Podiatric Medicine and Surgery, 2022).
Modern practice increasingly uses “superconstruct” principles, described by Sammarco and colleagues as four elements: extending fusion beyond the zone of injury, aggressive bone resection to permit reduction without soft-tissue tension, implants stronger than those used in non-neuropathic fusion, and placement that maximizes mechanical stability so devices become load-sharing (Sammarco et al., Instructional Course Lectures, 2024). Complication rates remain substantial, which is why nonsurgical management is attempted first in most cases.
Clinical Summary
Active Charcot neuro-osteoarthropathy is a clinical diagnosis made on suspicion, not confirmation. In a neuropathic diabetic foot, unilateral warmth, swelling and redness warrant immediate offloading while infection is excluded. Prolonged immobilization until radiographic and thermal quiescence remains the evidence-supported foundation of treatment, with surgical reconstruction reserved for chronic, unbraceable deformity. Rising population rates of CN and associated amputations underline the value of standardized diagnostic pathways and sustained patient education.
References
- Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3646. doi:10.1002/dmrr.3646
- Cole KA, Jupiter DC. Charcot neuroarthropathy in diabetic patients in Texas. Primary Care Diabetes. 2024;18(5):533–538. doi:10.1016/j.pcd.2024.06.012
- Bansod H, Wanjari A, Dumbhare O. A review on relationship between Charcot neuroarthropathy and diabetic patients. Cureus. 2023;15(12):e50988. doi:10.7759/cureus.50988
- Pham HT, Sanders E, Mendeszoon ER, Tseng W. Charcot neuroarthropathy versus osteomyelitis: a case series. Wounds. 2023;35(6):E203–E208. doi:10.25270/wnds/22063
- Schweitzer M, Rockhill S. Conservative management of Charcot neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):585–594. doi:10.1016/j.cpm.2022.05.005
- Spingola HD, Martucci J, DiDomenico LA. Plate fixation in midfoot and ankle Charcot neuroarthropathy. Clinics in Podiatric Medicine and Surgery. 2022;39(4):675–693. doi:10.1016/j.cpm.2022.06.001
- Sammarco VJ, Sammarco JA, Baratz ME, Sammarco GJ. Midfoot fusion using superconstructs for the Charcot foot: current techniques and complications. Instructional Course Lectures. 2024;73:231–245.
Comments
